Listen
Reason for request
: Inclusion on the list of medicines reimbursed by National Insurance and approved for use in hospital in the indication: symptomatic treatment of moderate to severe idiopathic Restless Legs
-
Clinical Benefit
| Insufficient |
The actual benefit of SIFROL is insufficient for all other forms. |
| Substantial |
The actual benefit of SIFROL will be substantial in very severe forms of idiopathic RLS. |
Clinical Added Value
| minor |
SIFROL share the same the level of ASMR IV with ADARTREL (ropinirole) in the management of patients with very severe idiopathic restless legs syndrome. |
Contact Us
Évaluation des médicaments
